{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:51:46Z","timestamp":1787014306396,"version":"build-2736575974"},"reference-count":18,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>As two\u2010drug HIV\u20101 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti\u2010HBc). Here, we assessed the safety and efficacy of dolutegravir\/lamivudine (DTG\/3TC) versus three\u2010 or four\u2010drug regimens (3DRs\/4DRs) among people with HIV\u20101 and isolated reactive anti\u2010HBc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were evaluated from GEMINI\u20101, GEMINI\u20102, STAT, TANGO and SALSA at various time points, including Weeks 48, 96, 144 and 196. Participants had hepatitis B virus (HBV) exposure, isolated reactive anti\u2010HBc serology, no HBV infection and were naive to ART (GEMINI\u20101\/\u20102, STAT) or virologically suppressed before switching (TANGO, SALSA). All studies except STAT had a 3DR\/4DR comparator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 2798 participants, 76 (DTG\/3TC,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200944; 3DR\/4DR,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200932) had isolated reactive anti\u2010HBc. Across studies, no instances of HBV reactivation occurred, and liver chemistry elevations were infrequent and generally mild. Among those naive to ART at baseline and receiving DTG\/3TC, 78% (18\/23) achieved HIV\u20101 RNA &lt;50 copies\/mL at Week 144 in GEMINI\u20101\/\u20102, and 60% (3\/5) achieved HIV\u20101 RNA &lt;50 copies\/mL at Week 48 in STAT. Among participants with virologic suppression at baseline who switched from 3DR\/4DR to DTG\/3TC, none experienced HIV\u20101 RNA \u226550 copies\/mL at the end of TANGO (Week 196) or SALSA (Week 48). HIV\u20101 suppression rates were comparable to those of 3DRs\/4DRs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis provides new information about DTG\/3TC treatment for people with HIV\u20101 and isolated reactive anti\u2010HBc. There were high rates of HIV\u20101 suppression with DTG\/3TC, no cases of HBV reactivation and no new safety signals identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70237","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:14:57Z","timestamp":1776399297000},"page":"1189-1195","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of dolutegravir\/lamivudine in adults with\n                    <scp>HIV<\/scp>\n                    \u20101 and isolated reactive hepatitis B core antibody: Insights from Phase 3\/3b study results"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6418-5966","authenticated-orcid":false,"given":"D.","family":"Fox","sequence":"first","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Slim","sequence":"additional","affiliation":[{"name":"New York Medical College  Valhalla New York USA"},{"name":"Saint Michael's Medical Center  Newark New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. T.","family":"Overton","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Doblado\u2010Maldonado","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jeffery","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Grove","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. D.","family":"Advani","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Borsi","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Parry","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Underwood","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12716"},{"issue":"1","key":"e_1_2_11_3_1","first-page":"14","article-title":"Chronic hepatitis B and HIV coinfection","volume":"31","author":"Corcorran MA","year":"2023","journal-title":"Top Antivir Med"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003395"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad101"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003070"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-2-82"},{"key":"e_1_2_11_9_1","volume-title":"Viral Hepatitis. Hepatitis B Surveillance Guidance","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"e_1_2_11_10_1","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2025"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0379-y"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010202"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16030348"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003239"},{"key":"e_1_2_11_16_1","volume-title":"EACS Guidelines Version 12.1, Novemer 2024","author":"European AIDS Clinical Society","year":"2024"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004227"},{"key":"e_1_2_11_18_1","unstructured":"SalpiniR D'AnnaS AlkhatibM et al.Reactivation of hepatitis B virus is a frequent event in anti\u2010HBc positive\/HBsAg\u2010negative HIV\u2010infected patients switching to tenofovir sparing therapy as revealed by highly sensitive HBV assays. Presented at: ICAR; May 30\u2013June 3.2022; Montreal QC Canada."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.106"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:09:31Z","timestamp":1783447771000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/hiv.70237"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70237","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"2025-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}